Lepu Biopharma (HKG:2157) said results from its Phase IIb study of MRG003, an antibody drug conjugate for treating recurrent or metastatic nasopharyngeal cancer, were selected as a late-breaking abstract for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting, according to a Thursday filing on the Hong Kong Exchange.
MRG003 targets epidermal growth factor receptor (EGFR), which is highly expressed in various cancers, including colorectal, lung, and head and neck cancers, and 89% of advanced nasopharyngeal cancer cases.
The drug combines an EGFR-targeted monoclonal antibody with a microtubulin inhibitor payload, designed to kill tumor cells after internalization.
Lepu cautioned there is no assurance that MRG003 will be successfully developed and marketed.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。